Nektar Therapeutics (NKTR)
$21.13 0.64 (2.94%)
19:58 EST NKTR Stock Quote Delayed 15 Minutes
Previous Close $21.13
Market Cap 3.62B
PE Ratio -26.41
Volume (Avg. Vol.) 1.90M
Day's Range 20.61 - 21.81
52-Week Range 15.64 - 47.11
Dividend & Yield N/A (N/A)
NKTR Stock Predictions, Articles, and Nektar Therapeutics News
- From InvestorPlace
- From the Web
While the markets have roared higher in 2019, these stocks have been crashing. But some of them could rebound soon.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Stock charts of VRTX, NKTR and SYMC are going to end the trading week knocking on the door of major moves.
All-American U.S. stocks like Foot Locker, Copart and Snapchat are on the mend for all the right reasons. here are the charts to watch.
As we move into the weekend, the stock charts of AOS, NKTR and WAT should be on your radar.
Sellers dominated the trading action on Nektar stock after its preliminary clinical results. Over-reaction or justified selling? The market simply did not understand the results, hurting the NKTR stock price.
Bristol-Myers Squibb Company (BMY) shares were sliding as the company's collaboration cancer drug with Nektar Therapeutics (NKTR) did not impress investors.
Nektar Therapeutics (NKTR) took a heavy hit on Monday following the release of preliminary results from a recent clinical trial.
Nektar Therapeutics pulled back in recent weeks, and that is a good thing. Valuations are stretched, but the upside in NKTR stock is high if management delivers.
3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies Inc (SEDG)
Alphabet Inc (GOOG,GOOGL) is fixing latency issues with Google Home Max, while Nektar Therapeutics (NKTR) and Solaredge Technologies Inc (SEDG) reported earnings.
In the end, the Dow lost a fraction, the S&P gave back 0.2%, the Nasdaq gained a fraction and the Russell 2000 finished the day 0.5% lower.
The overall ratings of 16 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
From Market News Video
Investors in Nektar Therapeutics (NKTR) saw new options begin trading today, for the March 6th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new March 6th contracts and identified one put and one call contract of particular interest.
From Analyst Ratings
In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report), with a price target of $24.00. The company’s shares closed last Monday at $22.48. According to TipRanks.com, Olson has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.6%
Navellier RatingsPowered by Portfolio Grader